SCM
DMAAR

Shaolin Capital Management’s Drugs Made In America Acquisition Corp Rights DMAAR Stock Holding History

Shaolin Capital Management’s Portfolio DMAAR Stock Details DMAAR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$33K Sell
300,000
-150,000
-33% -$15.5K ﹤0.01% 515
2026
Q1 		$27.2K Sell
450,000
-150,000
-25% -$15.9K ﹤0.01% 472
2025
Q4 		$112K Buy
600,000
+25,000
+4% +$4.85K ﹤0.01% 309
2025
Q3 		$125K Buy
+575,000
New +$107K 0.01% 233

Other funds holding DMAAR

PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $6.07B AUM 34.81% 1-Year Est. Return
LA
Linden Advisors New York $19.3B AUM 1.47% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.52B AUM 36.54% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $36.8B AUM 42.13% 1-Year Est. Return
CS
Clear Street New York $39.5B AUM 124.03% 1-Year Est. Return
HCM
Highbridge Capital Management New York $4.11B AUM 26.03% 1-Year Est. Return
RCM
Rivernorth Capital Management West Palm Beach, Florida $2.1B AUM 2.15% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
AGM
Alpine Global Management New York $615M AUM 34.28% 1-Year Est. Return

Shaolin Capital Management's DMAAR Position: Q2 2026 in Review

Shaolin Capital Management reduced its Drugs Made In America Acquisition Corp Rights (DMAAR) stake by 33% in Q2 2026, selling an estimated $15.5K and leaving 300,000 shares worth $33K. The position accounts for ﹤0.01% of the portfolio, ranked #515.

Shaolin Capital Management first reported a position in DMAAR in Q3 2025 and has held it in 4 quarters since. The position peaked at $125K in Q3 2025. 28 funds tracked by Wall St. Rank hold DMAAR as of Q2 2026.

  • Shaolin Capital Management held 300,000 shares of Drugs Made In America Acquisition Corp Rights worth $33K as of Q2 2026.
  • Shaolin Capital Management sold 150,000 Drugs Made In America Acquisition Corp Rights shares in Q2 2026, an estimated $15.5K.
  • Drugs Made In America Acquisition Corp Rights made up ﹤0.01% of Shaolin Capital Management's portfolio in Q2 2026, its #515 holding.
  • Shaolin Capital Management first reported a position in Drugs Made In America Acquisition Corp Rights in Q3 2025 and has held it in 4 quarters since.
  • Shaolin Capital Management's Drugs Made In America Acquisition Corp Rights position peaked at $125K in Q3 2025.
  • 28 funds tracked by Wall St. Rank held Drugs Made In America Acquisition Corp Rights as of Q2 2026.

Based on Shaolin Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.